-
1Academic Journal
Authors: Golovach, I.Yu., Yehudina, Ye.D.
Source: Практична онкологія-Praktična onkologìâ; Том 2, № 3 (2019); 9-23
Practical oncology; Том 2, № 3 (2019); 9-23
Практическая онкология-Praktična onkologìâ; Том 2, № 3 (2019); 9-23Subject Terms: lymphoma, Sjogren's syndrome, lymphoproliferative diseases, prognostic markers, cryoglobulinemia, risk factors, diagnosis, лімфома, синдром Шегрена, лімфопроліферативне захворювання, прогностичні маркери, кріоглобулінемія, фактори ризику, діагностика, лимфома, лимфопролиферативное заболевание, прогностические маркеры, криоглобулинемия, факторы риска, диагностика, 3. Good health
File Description: application/pdf
-
2Academic Journal
Source: Клиническая онкогематология, Vol 14, Iss 4 (2021)
-
3Academic Journal
Analysis of combination of chronic myeloproliferative and lymphoproliferative disease in one patient
Source: ScienceRise: Medical Science; № 2 (29) (2019); 23-27
ScienceRise. Medical Science; № 2 (29) (2019); 23-27Subject Terms: миелопролиферативное заболевание, лимфопролиферативное заболевание, хроническая лимфоцитарная лейкемия, лимфома, полицитемия, миелофиброз, мієлопроліферативне захворювання, лімфопроліферативне захворювання, хронічна лімфоцитарна лейкемія, лімфома, поліцитемія, мієлофіброз, УДК: 616-006.446.6-06:616.155.392.2]-036.12, myeloproliferative disease, lymphoproliferative disease, chronic lymphocytic leukemia, lymphoma, polycythemia, myelofibrosis, 3. Good health
File Description: application/pdf
Access URL: http://journals.uran.ua/sr_med/article/download/161767/163493
http://journals.uran.ua/sr_med/article/view/161767
https://www.neliti.com/publications/313615/analysis-of-combination-of-chronic-myeloproliferative-and-lymphoproliferative-di
http://journals.uran.ua/sr_med/article/download/161767/163493
http://journals.uran.ua/sr_med/article/view/161767 -
4Academic Journal
Authors: S. A. Yakushyna, L. B. Kisteneva, S. G. Cheshyk, С. А. Якушина, Л. Б. Кистенева, С. Г. Чешик
Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 64, № 2 (2019); 38-46 ; Российский вестник перинатологии и педиатрии; Том 64, № 2 (2019); 38-46 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2019-64-2
Subject Terms: таргетная терапия, Epstein–Barr virus, chronic active Epstein–Barr viral infection, hemophagocytic lymphohistiocytosis, posttransplantation lymphoproliferative disease, treatment, target therapy, вирус Эпштейна–Барр, хроническая активная Эпштейна–Барр вирусная инфекция, гемофагоцитарный лимфогистиоцитоз, посттрансплантационное лимфопролиферативное заболевание, лечение
File Description: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/854/762; Cohen J.I. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481–492. DOI:10.1056/NEJM200008173430707.; Феклисова Л.В., Савицкая Н.А., Каражас Н.В., Бошьян Р.Е. Клинико-лабораторная оценка обнаружения маркеров оппортунистических инфекций у детей, больных ОРЗ с обструкцией дыхательных путей. Детские инфекции 2008; 7(4): 13–17.; Гончарова Е.В., Сенюта Н.Б., Смирнова К.В., Щербак Л.Н., Гурцевич В.Э. Вирус Эпштейна–Барр (ВЭБ) в России: инфицированность населения и анализ вариантов гена LMP1 у больных ВЭБ-ассоциированными патологиями и здоровых лиц. Вопросы вирусологии 2015; 60(2): 11–17.; Holmes R.D., Sokol R.J. Epstein–Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456–464. DOI:10.1034/j.1399-3046.2002.02043.x; Price A.M., Dai J., Bazot Q., Patel L., Nikitin P.A., Djavadian R. et al. Epstein–Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. Elife 2017; 6: e22509. DOI:10.7554/eLife.22509; Coleman C.B., Wohlford E.M., Smith N.A., King C.A., Ritchie J.A., Baresel P.C. et al. Epstein–Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphocytic cytokines. J Virol 2015 89(4): 2301–2312. DOI:10.1128/JVI.03001-14; Rickinson A. B., Kieff E. Epstein–Barr virus. In: D.M. Knipe, P.M. Howley (eds). Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA, 2007; 2655–2700.; Maruo S., Yang L., Takada K. Roles of Epstein–Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J Gen Virol 2001; 82(Pt 10): 2373–2383. DOI:10.1099/0022-1317-82-10-2373.; Odumade O.A., Hogquist K.A., Balfour H.H. Progress and problems in understanding and managing primary Epstein–Barr virus infections. ClinMicrobiol Rev 2011; 24(1): 193–209. DOI:10.1128/CMR.00044-10.; Kimura H., Cohen J.I. Chronic Active Epstein–Barr Virus Disease. Front Immunol 2017; 8: 1867. DOI:10.3389/fimmu.2017.01867; Cohen J.I. Optimal treatment for chronic active Epstein–Barr virus disease. Pediatr Transplant 2009; 13(4): 393–396. DOI:10.1111/j.1399-3046.2008.01095.x; Якушина С.А., Кистенева Л.Б. Влияние персистенции вируса Эпштейна–Барр на развитие иммуноопосредованных соматических заболеваний. Российский вестник перинатологии и педиатрии 2018; 63(1): 22–27. DOI:10.21508/1027–4065–2018–63–1–22–27.; Goudarzipour K., Kajiyazdi M., Mahdaviyani A. Epstein–Barr virus-induced hemophagocytic lymphohistiocytosis. Int J Hematol Oncol Stem Cell Res 2013; 7(1): 42–45.; Loebel M., Eckey M., Sotzny F., Hahn E., Bauer S., Grabowski P. et al. Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray. PLoS One 2017; 12(6): e0179124. DOI:10.1371/journal.pone.0179124; Rose C., Green M., Webber S., Kingsley L., Day R., Watkins S. et al. Detection of Epstein–Barr Virus Genomes in Peripheral Blood B Cells from Solid-Organ Transplant Recipients by Fluorescence In Situ Hybridization. J Clin Microbiol 2002; 40(7): 2533–2544. DOI:10.1128/JCM.40.7.2533-2544.2002; Mancao C., Hammerschmidt W. Epstein–Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007; 110(10): 3715–3721. DOI:10.1182/blood-2007-05-090142; Gershburg E., Pagano J.S. Epstein–Barr virus infections: prospects for treatment. J Antimicrob Chemother 2005; 56(2): 277–281. DOI:10.1093/jac/dki240; Pagano J.S., Whitehurst C.B., Andrei G. Antiviral Drugs for EBV. Cancers 2018; 10(6): 197. DOI:10.3390/cancers10060197; Moniri A., Tabarsi P., Marjani M., Doosti Z. Acute Epstein–Barr virus hepatitis without mononucleosis syndrome: a case report. Gastroenterol Hepatol Bed Bench 2017; 10(2): 147–149. DOI:10.22037/ghfbb.v0i0.930; Rafailidis P.I., Mavros M.N., Kapaskelis A., Falagas M.E. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol 2010; 49(3): 151–157. DOI:10.1016/j.jcv.2010.07.008; Hocker B., Bohm S., Fickenscher H., Kusters U., Schnitzler P., Pohl M. et al. (Val-) Ganciclovir prophylaxis reduces Epstein–Barr virus primary infection in pediatric renal transplantation. Transplant International 2012; 25: 723–731. DOI:10.1111/j.1432-2277.2012.01485.x; Coen N., Singh U., Vuyyuru V., Van den Oord J.J., Balzarini J., Duraffour S. et al. Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses. J Virol 2013; 87(7): 3839–3851. DOI:10.1128/JVI.03338-12; Whitehurst C.B., Sanders M.K., Law M., Wang F.-Z., Xiong J., Dittmer D.P. et al. Maribavir inhibits Epstein–Barr virus transcription through the EBV protein kinase. J Virol 2013; 87(9): 5311–5315. DOI:10.1128/JVI.03505-12; Coen N., Duraffour S., Topalis D., Snoeck R., Andrei G. Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses. Antimicrobal Agents and Chemotherapy 2014; 58(12): 7312–7323. DOI:10.1128/AAC.03957-14; Walling D.M., Flaitz C.M., Nichols C.M. 2003. Epstein–Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. JID 2003; 188: 883–890. DOI:10.1086/378072; Katano H., Ali M.A., Patera A.C., Catalfamo M., Straus S.E., Cohen J.I. et al. Chronic active Epstein–Barr virus infection associated with mutations in perforin that impair its maturation. Blood 2004; 103(4): 1244–1252. DOI:10.1182/blood-2003-06-2171; Ito Y., Shibata-Watanabe Y., Ushijima Y., Kawada J., Nishiyama Y., Kojima S., Kimura H. Oligonucleotide microarray analysis of gene expression profiles followed by real-time reverse-transcriptase polymerase chain reaction assay in chronic active Epstein–Barr virus infection. JID 2008; 197(5): 663–666. DOI:10.1086/527330; Sakai Y., Ohga S., Tonegawa Y., Takada H., Nakao F., Nakayama H. et al. Interferon-alpha therapy for chronic active Epstein–Barr virus infection: potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol 1998; 20(4): 342–346.; Малашенкова И.К., Дидковский Н.А., Сарсания Ж.Ш., Жарова М.А., Литвиненко Е.Н., Щепеткова И.Н. и др. Клинические формы хронической Эпштейна–Барр вирусной инфекции: вопросы диагностики и лечения. Лечащий врач 2003; 11–19.; Roliński J., Grywalska E., Pyzik A., Dzik M., Opoka-Viniarska V., Surdacka A. et al. Interferon alpha as antiviral therapy in chronic active Epstein–Barr virus disease with interstitial pneumonia – case report. BMC Infect Dis 2018; 18(1): 190. DOI:10.1186/s12879-018-3097-6; Imashuku S., Hibi S., Ohara T., Iwai A., Sako M., Kato M. et al. Effective control of Epstein–Barr virus-related hemo phagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society Blood 1999; 93: 1869–1874.; Cohen J.I., Jaffe E.S., Dale J.K., Pittaluga S.P., Heslop H.E., Straus S.E. et al. Characterization and treatment of chronic active Epstein–Barr virus disease: a 28-year experience in the United States. Blood 2011; 117(22): 5835–5849. DOI:10.1182/blood-2010-11-316745; Du F.H., Mills E.A., Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Autoimmunity Highlights 2017; 8(1): 12. DOI:10.1007/s13317-017-0100-y; Milone M.C., Tsai D.E., Hodinka R.L., Silverman L.B., Malbran A., Wasik M.A. et al. Treatment of primary Epstein–Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 2005; 105(3): 994–996. DOI:10.1182/blood-2004-07-2965; Xu L.P., Liu D.H., Liu K.Y., Zhang C.L., Wang F.R., Wang J.Z. et al. The efficacy and safety of rituximab in treatment of EpsteinBarr virus disease post allogeneic hematopoietic stem-cell transplantation. Zhonghua Nei Ke Za Zhi 2012; 51(12): 966–970.; Burns D.M., Rana S., Martin E., Nagra S., Ward J., Osman H. et al. Greatly reduced risk of EBV reactivation in rituximabexperienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplantation 2016; 51(6): 825–832. DOI:10.1038/bmt.2016.19; Dotti G., Gottschalk S., Savoldo B., Brenner M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257(1): 107–126. DOI:10.1111/imr.12131; DiGiusto D., Cooper L. Preparing clinical grade Ag-specific Tcells for adoptive immunotherapy trials. Cytotherapy 2007; 9(7): 613–629. DOI:10.1080/14653240701650320; Huang J., Fogg M., Wirth L.J., Daley H. Ritz J., Posner M.R. et al. Epstein–Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer 2017; 123(14): 2642–2650. DOI:10.1002/cncr.30541; Savoldo B., Huls M.H., Liu Z., Okamura T., Volk H.D., Reinke P. et al. Autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100(12): 4059–4066. DOI:10.1182/blood-2002-01-0039; Doubrovina E., Oflaz-Sozmen B., Prockop S.E., Kernan N.A., Abramson S., Teruya-Fildstein J. et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119(11): 2644–2656. DOI:10.1182/blood-2011-08-371971; Nijland M.L., Kersten M.J., Pals S.T., Bemelman F.J., Ten Berge I.J. Epstein–Barr Virus-Positive PosttransplantLymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplantation Direct 2015; 2(1): e48. DOI:10.1097/TXD.0000000000000557; Papadopoulou A., Gerdemann U., Katari U.L., Tzannou I., Liu H., Martinez C. et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Science Translational Medicine 2014; 6(242): 242ra83. DOI:10.1126/scitranslmed.3008825; Naik S., Nicholas S.K., Martinez C.A., Leen A.M., Hanley P.J., Gottschalk S.M. et al. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 2016; 137(5): 1498–1505.e1. DOI:10.1016/j.jaci.2015.12.1311; Heslop H.E., Slobod K.S., Pule M.A., Hale J.A., Rousseau A., Smith C.A. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115(5): 925–935. DOI:10.1182/blood-2009-08-239186; McLaughlin L.P., Bollard C.M., Keller M.D. Adoptive T Cell Therapy for Epstein–Barr Virus Complications in Patients With Primary Immunodeficiency Disorders. Front Immunol 2018; 9: 556. DOI:10.3389/fimmu.2018.00556; Gotoh K., Ito Y., Shibata-Watanabe Y., Kawada J., Takahashi Y., Yagasaki H. et al. Clinical and virological characteristics of 15 patients with chronic active Epstein–Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46(10): 1525–1534. DOI:10.1086/587671; Afessa B., Peters S.G. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 2006; 27(3): 297–309. DOI:10.1055/s-2006-945530
-
5Academic Journal
Subject Terms: reactive lymphocytosis, Т-клеточный лейкоз из больших гранулярных лимфоцитов, T-cell large granular lymphocytic leukemia, клональные реаранжировки, large granular lymphocytes, flow cytometry, большие гранулярные лимфоциты, хроническое лимфопролиферативное заболевание NK-клеток, ПЦР-исследование Т-клеточной клональности, PCR-based T-cell clonality testing, проточная цитометрия, chronic lymphoproliferative disorder of NK-cells, 3. Good health
-
6Academic Journal
Authors: БЕСЕДОВСКАЯ НАТАЛЬЯ АНДРЕЕВНА, ЗАГРЕБНЕВА А.И.
Subject Terms: КРИОГЛОБУЛИНЕМИЧЕСКИЙ ВАСКУЛИТ, ЛИМФОПРОЛИФЕРАТИВНОЕ ЗАБОЛЕВАНИЕ
File Description: text/html
-
7Academic Journal
Source: Лечебное дело.
File Description: text/html
-
8Academic Journal
Source: Российский медико-биологический вестник имени академика И.П. Павлова.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ИММУННЫЙ СТАТУС,IMMUNE STATUS,ЛИМФОПРОЛИФЕРАТИВНОЕ ЗАБОЛЕВАНИЕ,LYMPHOPROLIFERATIVE DISEASE,ОППОРТУНИСТИЧЕСКАЯ ИНФЕКЦИЯ,OPPORTUNISTIC INFECTION, 3. Good health
File Description: text/html
-
9Academic Journal
Authors: Щербакова, Е. Н., Малаева, Е. Г., Остапова, Е. В.
Subject Terms: болезнь Кастлемана, мультицентрическая болезнь Кастлемана, лимфопролиферативное заболевание, Castleman disease, multicentric Castleman disease, lymphoproliferative disease
Relation: Щербакова, Е. Н. Мультицентрический вариант болезни Кастлемана / Е. Н. Щербакова, Е. Г. Малаева, Е. В. Остапова// Проблемы здоровья и экологии. - 2019. - № 3 (61). – С. 97-101.; http://elib.gsmu.by/handle/GomSMU/6221
Availability: http://elib.gsmu.by/handle/GomSMU/6221
-
10Academic Journal
Authors: Стуклов Н.И., Вернюк М.А., Парфенова О.А., Червонцева А.М., Черкашина И.В., Гущина Е.Е., Кислый Н.Д.
Source: Гематология. Трансфузиология. Восточная Европа
Subject Terms: lymphoproliferative disease, primary gastric lymphoma, clinical features, diagnosis of extranodal lymphomas, лимфопролиферативное заболевание, лимфома с первичным поражением желудка, клинические особенности, диагностика экстранодальных лимфом
Availability: https://repository.rudn.ru/records/article/record/95130/
